Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Intensity Modulated Total Marrow Irradiation (IM-TMI) for Advanced Hematologic Malignancies

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Damiano Rondelli, MD, University of Illinois at Chicago
ClinicalTrials.gov Identifier:
NCT00988013
First received: September 30, 2009
Last updated: April 30, 2014
Last verified: April 2014

September 30, 2009
April 30, 2014
September 2009
September 2016   (final data collection date for primary outcome measure)
To determine the overall toxicity and day 100 transplant related mortality [ Time Frame: Up do 100 days post-transplant ] [ Designated as safety issue: Yes ]
To determine the overall toxicity and day 100 transplant related mortality [ Time Frame: First 100 days after transplant ] [ Designated as safety issue: Yes ]
Complete list of historical versions of study NCT00988013 on ClinicalTrials.gov Archive Site
To determine the time to neutrophil and platelet engraftment in patients with hematologic malignancies [ Time Frame: Up to 100 days post-transplant ] [ Designated as safety issue: Yes ]
To determine the time to neutrophil and platelet engraftment in patients with hematologic malignancies [ Time Frame: First 100 days after transplant ] [ Designated as safety issue: Yes ]
Not Provided
Not Provided
 
Intensity Modulated Total Marrow Irradiation (IM-TMI) for Advanced Hematologic Malignancies
A Phase I Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Fludarabine/Busulfan Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies

This is a phase I study using Intensity Modulated Total Marrow Irradiation (IM-TMI) in addition to a chemotherapy regimen in preparation for an allogeneic stem cell transplant for advanced hematologic malignancies such as acute myeloid or lymphoblastic leukemia, high grade non Hodgkin's or Hodgkin's lymphoma, chronic myelogenous leukemia, and plasma cell leukemia. Because the subjects participating in this study have a disease that is severe and has a high risk of relapse even after transplant, the investigators propose to use a chemotherapy regimen (fludarabine/busulfan), the name for the combination of chemotherapy drugs that is given to patients prior to transplantation of the donor stem cells, along with intensity modulated radiation (IM-TMI) to the bone marrow. Total body irradiation (TBI) in conjunction with chemotherapy is a standard of care as a pre-conditioning regimen prior to bone marrow transplant (BMT) in patients with hematologic malignancies. However, TBI can cause severe side effects due to irradiation of organs such as the lenses of the eye, whole brain, lungs, liver, kidneys, heart, small bowel and oral cavity. IM-TMI allows for the delivery of adequate doses of radiation to the bone marrow while sparing other organs and therefore limiting radiation side effects. The irradiation, along with receiving the chemotherapy drugs will suppress the subject's immune system and kill off tumor cells, but will also intensify the effect of the conditioning regimen thus allowing the bone marrow transplantation to have a greater chance of being successful.

No investigational drugs are used in this study. The investigational part of this study is the use of intensity modulated total marrow irradiation instead of conventional radiation. IMTMI can deliver 99% of the prescribed treatment to the targeted bones and reduce the doses of radiation to surrounding organs, as received in conventional TBI, by 29% to 65%.

Not Provided
Interventional
Phase 1
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Acute Myeloid Leukemia
  • Lymphoblastic Leukemia
  • Acute Leukemia
  • Non Hodgkins Lymphoma
  • Chronic Myeloid Leukemia
  • Radiation: IM-TMI (3Gy)
    Patients will receive 3Gy per day for 1 day.
  • Radiation: IM-TMI (6Gy)
    Patients will receive 3Gy per day for 2 days.
  • Radiation: IM-TMI (9Gy)
    Patients will receive 3Gy per day for 3 days.
  • Radiation: IM-TMI (12Gy)
    Patients will receive 3Gy per day for 4 days.
  • Experimental: IM-TMI (3Gy)
    Patients will receive 3Gy per day for 1 day (total of 3Gy).
    Intervention: Radiation: IM-TMI (3Gy)
  • Experimental: IM-TMI (6Gy)
    Patients will receive 3Gy per day for 2 days (for a total of 6Gy).
    Intervention: Radiation: IM-TMI (6Gy)
  • Experimental: IM-TMI (9Gy)
    Patients will receive 3Gy per day for 3 days (for a total of 9Gy).
    Intervention: Radiation: IM-TMI (9Gy)
  • Experimental: IM-TMI (12Gy)
    Patients will receive 3Gy per day for 4 days (for a total of 12Gy).
    Intervention: Radiation: IM-TMI (12Gy)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
24
September 2016
September 2016   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients with the following diseases:

    • Acute myeloid or lymphoblastic leukemia in first complete remission if poor prognosis documented by failure to response after initial induction chemotherapy, or cytogenetic, or molecular studies.
    • Acute leukemia in greater/equal second remission, or partial remission after chemotherapy.
    • High grade non Hodgkin's or Hodgkin's lymphoma with marrow involvement resistant/ relapsed after second line therapy including high dose chemotherapy and autologous SCT.
    • CML in advanced or blastic phase.
    • Plasma cell leukemia.
  • Age 18-60 years.
  • Karnofsky performance status of 70
  • Adequate cardiac and pulmonary function. Patients with decreased LVEF less than/equal to 40% or DLCO less than/equal to 50% of predicted will require clearance from cardiology or pulmonary services, respectively, prior to enrollment on this protocol.
  • Serum creatinine less than/equal to 1.5 mg/dL or Creatinine Clearance greater than/equal to 50 ml/min .
  • Serum bilirubin 2.0 mg/dl, SGPT less than/equal to 3 times the upper limit of normal

Exclusion Criteria:

  • Life expectancy is severely limited by concomitant illness.
  • Evidence of chronic active hepatitis or cirrhosis
  • HIV-positive
  • Patient is pregnant
  • Patient or guardian is not able to sign informed consent.
Both
18 Years to 60 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00988013
2009-0251
Yes
Damiano Rondelli, MD, University of Illinois at Chicago
University of Illinois at Chicago
Not Provided
Study Chair: Damiano Rondelli, MD University of Illinois at Chicago
University of Illinois at Chicago
April 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP